David Rees (organic chemist)
David Charles Rees (born 1958) CChem FRSC FMedSci is a chemist recognised internationally for his innovative use of chemistry in drug discovery.[5] He is Chief Scientific Officer of biotechnology company Astex Pharmaceuticals, which is located in Cambridge, UK.
David Charles Rees | |
|---|---|
![]() | |
| Born | 1958 (age 62–63) |
| Alma mater | University of Southampton (BSc), University of Cambridge (PhD) |
| Known for | Astex |
| Awards | Royal Society of Chemistry, Malcolm Campbell Award 2007[1]
Royal Society of Chemistry BMCS Hall of Fame 2020[2] Royal Society of Chemistry BMCS Lectureship 2021/2022[3] Fellowships Fellow of the Royal Society of Chemistry Fellow of the Academy of Medical Sciences (2020) |
| Scientific career | |
| Fields | Drug discovery, Medicinal chemistry, Organic chemistry |
| Institutions | Astex, AstraZeneca, Organon |
| Thesis | A new approach to the synthesis of aspidosperma alkaloids using tricarbonylcyclohexadienylium iron intermediates[4] |
| Website | astx |
Career
David joined Astex in 2003 to lead its chemistry team. He became Chief Scientific Officer (CSO) in 2017.[6] In 2013, Astex was acquired for around USD $900 million[7] and now operates as a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd, headquartered in Tokyo, Japan.
Rees is associated with the discovery of three launched drugs: ribociclib (Astex-Novartis collaboration),[8] erdafitinib (Astex-Janssen collaboration)[9] as well as the anaesthetic reversal agent sugammadex (Organon, Merck),[10] which has been used in over 30 million patients in 60 countries and had global sales of US$1.2 billion in 2020.[11]
Rees has a BSc from the University of Southampton and PhD from the University of Cambridge.
Fellowships, Awards, and Academic Appointments
David is a Fellow of the Royal Society of Chemistry (RSC). He is one of the few industrial scientists to have served as President of its Organic Division (2010-2013), and was later elected to the RSC Board of Trustees (2015-2019).[12]
Rees has held visiting professorships at three UK universities, and sits on several scientific advisory boards for not-for-profit organisations. In 2020 he was elected as a Fellow of the Academy of Medical Sciences and inducted into the RSC BMCS Hall of Fame.[13] He has over 140 publications and patents.
Rees is also a Director of Ashanti Development, a charity that promotes clean water and sanitation in Ghana.
More reading
References
- "BMCS Malcolm Campbell Award". Retrieved 2019-04-30.
- BMCS Hall of Fame, retrieved 2021-11-01
- Lectureship 20-22 - awardees (PDF), retrieved 2021-11-01
- Rees, D. C. (1982). e-theses online service (Ph.D). University of Cambridge. Retrieved 2019-04-30.
- ""david rees - Google Scholar Citations"". Retrieved 2019-04-24.
- "David Rees". Astex website.
- Reuters Staff (2013-09-04). "Japan's Otsuka to buy Astex Pharma for about $900 million: Nikkei". Reuters. Retrieved 14 April 2021.
- "Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval".
- "Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval".
- Bom, Anton; Bradley, Mark; Cameron, Ken; Clark, John K.; Egmond, Jan van; Feilden, Helen; MacLean, Elizabeth J.; Muir, Alan W.; Palin, Ronald (2002). "A Novel Concept of Reversing Neuromuscular Block: Chemical Encapsulation of Rocuronium Bromide by a Cyclodextrin-Based Synthetic Host". Angewandte Chemie International Edition. 41 (2): 265–70. doi:10.1002/1521-3773(20020118)41:2<265::AID-ANIE265>3.0.CO;2-Q. PMID 12491405.CS1 maint: multiple names: authors list (link)
- "Merck & Co., Inc. Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2018" (PDF).
- "The Royal Society of Chemistry - our structure". Retrieved 24 April 2019.
- "BMCS Hall of Fame and Medal". RSC BMCS website. Retrieved 26 May 2021.
